Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

1.

Current status of radiosensitizing agents for the management of rectal cancer.

Illum H.

Crit Rev Oncog. 2012;17(4):345-59. Review.

PMID:
23176042
[PubMed - indexed for MEDLINE]
2.

Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin.

Martin LK, Bekaii-Saab T.

J Natl Compr Canc Netw. 2013 Mar 1;11(3):298-307; quiz 307. Review.

PMID:
23486456
[PubMed - indexed for MEDLINE]
3.

Irinotecan and radiosensitization in rectal cancer.

Illum H.

Anticancer Drugs. 2011 Apr;22(4):324-9. doi: 10.1097/CAD.0b013e3283425c14. Review.

PMID:
21160419
[PubMed - indexed for MEDLINE]
4.

Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.

Patel PA.

Anticancer Drugs. 2011 Apr;22(4):311-6. doi: 10.1097/CAD.0b013e3283441a63. Review.

PMID:
21301320
[PubMed - indexed for MEDLINE]
5.

Toward the non-surgical management of locally advanced rectal cancer.

Dewdney A, Cunningham D.

Curr Oncol Rep. 2012 Jun;14(3):267-76. doi: 10.1007/s11912-012-0234-z. Review.

PMID:
22460631
[PubMed - indexed for MEDLINE]
6.

Role of combined-modality therapy in the management of locally advanced rectal cancer.

Hosein PJ, Rocha-Lima CM.

Clin Colorectal Cancer. 2008 Nov;7(6):369-75. doi: 10.3816/CCC.2008.n.049. Review.

PMID:
19036689
[PubMed - indexed for MEDLINE]
7.

The need for effective radiosentitizing agents: experience in patients with complete pathological response.

Habr-Gama A, Perez RO, São Julião GP, Proscurshim I, Gama-Rodrigues J.

Anticancer Drugs. 2011 Apr;22(4):308-10. doi: 10.1097/CAD.0b013e3283428193. Review.

PMID:
21150774
[PubMed - indexed for MEDLINE]
8.

Oxaliplatin as a radiosensitizing agent in rectal cancer.

Huerta S, Hrom J.

Anticancer Drugs. 2011 Apr;22(4):317-23. doi: 10.1097/CAD.0b013e328343e076. Review.

PMID:
21285866
[PubMed - indexed for MEDLINE]
9.

The role of targeted agents in preoperative chemoradiation for rectal cancer.

Wadlow RC, Ryan DP.

Cancer. 2010 Aug 1;116(15):3537-48. doi: 10.1002/cncr.25155. Review.

PMID:
20564106
[PubMed - indexed for MEDLINE]
Free Article
10.

The predictive value of clinical evaluation of response to neoadjuvant chemoradiation therapy for rectal cancer.

Benzoni E, Cerato F, Cojutti A, Milan E, Pontello D, Chiaulon G, Sacco C, Bresadola V, Terrosu G.

Tumori. 2005 Sep-Oct;91(5):401-5.

PMID:
16459636
[PubMed - indexed for MEDLINE]
11.

Should preoperative or postoperative therapy be administered in the management of rectal cancer?

Kachnic LA.

Semin Oncol. 2006 Dec;33(6 Suppl 11):S64-9. Review.

PMID:
17178291
[PubMed - indexed for MEDLINE]
12.

Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy.

Lee-Kong SA, Ruby JA, Chessin DB, Pucciarelli S, Shia J, Riedel ER, Nitti D, Guillem JG.

Dis Colon Rectum. 2012 Sep;55(9):990-5. doi: 10.1097/DCR.0b013e31825bd80c.

PMID:
22874607
[PubMed - indexed for MEDLINE]
13.

The contribution of targeted therapy to the neoadjuvant chemoradiation of rectal cancer.

Torino F, Sarmiento R, Gasparini G.

Crit Rev Oncol Hematol. 2013 Sep;87(3):283-305. doi: 10.1016/j.critrevonc.2013.02.002. Epub 2013 Mar 9. Review.

PMID:
23478150
[PubMed - indexed for MEDLINE]
14.

Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.

Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, Luppi G, Conte PF.

Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1455-61. Epub 2007 Apr 18.

PMID:
17445998
[PubMed - indexed for MEDLINE]
15.

[Neoadjuvant chemoradiotherapy of rectal carcinoma with bevacizumab].

Slampa P.

Klin Onkol. 2011;24(5):338-42. Review. Czech.

PMID:
22070014
[PubMed - indexed for MEDLINE]
16.

The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.

Huh JW, Min JJ, Lee JH, Kim HR, Kim YJ.

Am J Clin Oncol. 2012 Aug;35(4):340-4. doi: 10.1097/COC.0b013e3182118e7d.

PMID:
21422901
[PubMed - indexed for MEDLINE]
17.

Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.

Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, Wenz F, Hochhaus A, Post S, Willeke F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren).

Anticancer Drugs. 2009 Jul;20(6):519-24. doi: 10.1097/CAD.0b013e32832b53ff.

PMID:
19436196
[PubMed - indexed for MEDLINE]
18.

Alternative clinical end points in rectal cancer--are we getting closer?

Glynne-Jones R, Mawdsley S, Pearce T, Buyse M.

Ann Oncol. 2006 Aug;17(8):1239-48.

PMID:
16873440
[PubMed - indexed for MEDLINE]
Free Article
19.

[Exploration on neoadjuvant chemoradiation in the treatment for locally advanced low rectal cancer].

Yu BM, Zhang M, Peng LH, Bian GW, Wu WQ, Chen LW, Fu J, Fei CS.

Zhonghua Wai Ke Za Zhi. 2009 Oct 15;47(20):1540-3. Chinese.

PMID:
20092741
[PubMed - indexed for MEDLINE]
20.

The current landscape of locally advanced rectal cancer.

Aklilu M, Eng C.

Nat Rev Clin Oncol. 2011 Aug 9;8(11):649-59. doi: 10.1038/nrclinonc.2011.118. Review.

PMID:
21826084
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk